Frankfurt, Germany-based ERGOMED Group, a specialized international clinical development company, has opened a new facility in Russia. At the same time, the firm is appointing Sergei Drapkin - who was a co-found of Quintiles Transnational's Moscow branch - as the managing director for the Russian office.
The new office, which strengthens ERGOMED's position in Eastern Europe and Central Asia, will support ongoing operations in Russia, Ukraine, Kazakhstan and Belorussia. These countries represent emerging regions with very significant potential for high patient recruitment. Clinical research in the German firm's areas of specialization in these regions is also of a high quality, given the generally high standard of medical training and the concentration of medical expertise in a few centers, it claims.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze